Cytophage Technologies（CPTC.F）株式概要バイオテクノロジー企業であるサイトファージ・テクノロジーズ社（Cytophage Technologies Ltd.）は、カナダにおいて、人の健康、動物の健康、食糧安全保障に影響を及ぼす細菌感染症を治療するバクテリオファージ療法の研究、開発、商業化に従事している。 詳細CPTC.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( CA$0 )株式の流動性は非常に低い 意味のある時価総額がありません ( $11M )すべてのリスクチェックを見るCPTC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.21該当なし内在価値ディスカウントEst. Revenue$PastFuture-8m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesCytophage Technologies Ltd. 競合他社BioCardiaSymbol: NasdaqCM:BCDAMarket cap: US$10.0mRegentis BiomaterialsSymbol: NYSEAM:RGNTMarket cap: US$11.1mAprea TherapeuticsSymbol: NasdaqCM:APREMarket cap: US$11.1mMoleculin BiotechSymbol: NasdaqCM:MBRXMarket cap: US$12.8m価格と性能株価の高値、安値、推移の概要Cytophage Technologies過去の株価現在の株価CA$0.2152週高値CA$0.2152週安値CA$0.14ベータ0.161ヶ月の変化0%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化4.92%最新ニュースお知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.最新情報をもっと見るRecent updatesお知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.株主還元CPTC.FUS BiotechsUS 市場7D0%1.2%1.0%1Yn/a34.9%28.7%株主還元を見る業界別リターン: CPTC.FがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CPTC.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CPTC.F's price volatile compared to industry and market?CPTC.F volatilityCPTC.F Average Weekly Movementn/aBiotechs Industry Average Movement11.0%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: CPTC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCPTC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aSteven Theriaultcytophage.comバイオテクノロジー企業であるサイトファージ・テクノロジーズ社は、カナダで人の健康、動物の健康、食糧安全保障に影響を与える細菌感染症を治療するバクテリオファージ療法の研究、開発、商業化に従事している。AviPhageの名称で家禽健康製品を、PhageFendの名称で食品安全製品を、BoviPhageの名称で牛乳房炎製品を、FarmPhageの名称で家畜生産者向け水溶性溶液を開発している。本社はカナダのウィニペグ。もっと見るCytophage Technologies Ltd. 基礎のまとめCytophage Technologies の収益と売上を時価総額と比較するとどうか。CPTC.F 基礎統計学時価総額US$11.01m収益（TTM）-US$3.30m売上高(TTM)n/a0.0xP/Sレシオ-3.3xPER（株価収益率CPTC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CPTC.F 損益計算書（TTM）収益CA$0売上原価CA$0売上総利益CA$0その他の費用CA$4.62m収益-CA$4.62m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.075グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%CPTC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/18 22:40終値2025/07/21 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cytophage Technologies Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.
お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.
お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.
お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.
お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.
お知らせ • Jan 21Cytophage Technologies Ltd. Announces Chief Financial Officer ChangesCytophage Technologies Ltd. announced the appointment of James Kinley, CPA CA, as Chief Financial Officer. Mr. Kinley is based in Winnipeg and brings extensive experience in the biotech industry, having served as a CFO to several publicly listed healthcare companies over the past 15 years, including his current engagement as CFO to Algernon Health Inc. He will work with management and the Board of Directors to ensure continued compliance with the Company's financial reporting obligations and the requirements of applicable securities regulators and the TSX Venture Exchange. As a fractional CFO, the Company will also be able to benefit from cost savings in the appointment of Mr. Kinley. Mr. Kinley replaces Julius Kalcevich who has been the Company’s CFO since July 2023. Mr. Kalcevich was brought on to take the Company public through a reverse takeover and lead several financing efforts. Mr. Kalcevich has agreed to assist with an orderly transition and will work closely with Mr. Kinley to support continuity of financial oversight, reporting, and public company compliance during the transition period. Mr. Kalcevich will remain available to the Company as an ad-hoc independent consultant.
お知らせ • Nov 29Cytophage Technologies Ltd. announced that it has received CAD 1.2 million in fundingOn November 28, 2025, the company has closed the transaction. The company has issued 990,000 Units at a price of CAD 0.2 per unit for aggregate proceeds of CAD198,000. In connection with the closing, the Company has also agreed, subject to receiving Exchange approval, to pay finder’s fees of CAD4,200 in cash and to 21,000 broker warrants, on the same terms as the Warrants forming part of the Offering, to qualified non related parties. The closing of the Offering remains subject to all regulatory approvals from the TSX Venture Exchange.
お知らせ • Oct 17Cytophage Technologies Ltd. announced that it expects to receive CAD 1.2 million in fundingCytophage Technologies Ltd. announced a non-brokered private placement of up to 6,000,000 units at CAD 0.20 per Unit , for gross proceeds of up to CAD 1,200,000. Each Unit consists of one common share of the Company and one half of a common share purchase warrant. Each whole Warrant entitles the holder thereof to purchase one additional Share at a price of CAD 0.40 per Warrant Share, for a period of 24 months from the date of issuance. The Company reserves the right to increase the size of the Offering by up to an additional CAD 600,000 through the sale of up to 3,000,000 additional Units. All securities issued under the Offering, including Warrant Shares issuable upon exercise of the warrants and finders warrant shares issuable upon exercise of the Finders Warrants, will be subject to a hold period expiring 4 months and 1 day after each applicable closing date, in accordance with the rules and policies of the TSX Venture Exchange and applicable Canadian securities laws. The Company may close the Offering in multiple tranches. With the pending regulatory approvals from the TSX Venture Exchange, the Company expects to close the Offering on or about November 6, 2025.
お知らせ • Jun 11Cytophage Technologies Ltd. announced that it has received CAD 1.55 million in fundingOn June 10, 2025, Cytophage Technologies Ltd. closed the transaction. In connection with offering company paid pay finders' fees of CAD 27,545 in cash and issue 128,975 broker warrants. All securities issued are subject to a four-month hold period expiring Oct. 11, 2025.The company's directors and senior officers have collectively subscribed for 1,212,500 units for CAD 242,500, representing approximately 15.7 per cent of the total offering.
お知らせ • May 14Cytophage Technologies Ltd. announced that it expects to receive CAD 1 million in fundingCytophage Technologies Ltd announced a non brokered private placement to issue 5,000,000 units at a price of CAD 0.2 per unit for aggregate gross proceeds of CAD 1,000,000 on May 14, 2025. Each unit consists of one common share of the company and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one additional common share of the company at a price of CAD 0.4 per warrant share for a period of 24 months from the date of issuance. The company has received commitments from its directors and officers to subscribe for approximately 1,000,000 units, for gross proceeds of approximately CAD 200,000. The company anticipates closing the offering in multiple tranches. Pending all regulatory approvals from the TSX Venture Exchange, the company expects to close the first tranche of the offering on or about May 22, 2025. The company may pay finder’s fees of up to 7% of gross proceeds raised and issue warrants, on the same terms as the Warrants forming part of the units, of up to 7% of the number of units sold to investors, to qualified non-related parties, in accordance with the policies of the exchange. All securities issued under the offering, including warrant shares issuable on exercise of the Warrants, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws.
お知らせ • Apr 30Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025Cytophage Technologies Ltd., Annual General Meeting, Jun 25, 2025.
